Inhibikase Therapeutics, Inc.IKTNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank63
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Latest
-5.88%
↑ 96% vs avg
Percentile
P63
Within normal range
Streak
1 yr
Consecutive declineDecelerating
Average
-137.81%
Historical baseline
PeriodValue
2024-5.88%
2023-4.23%
2022-21.36%
2021-1165.95%
2020-233.84%
2019-147.31%
2018665.69%
2017-327.39%
20160.00%